ReEir Co., Ltd.

Founded in 2017 and based in Tokyo, Japan, ReEir Co. , Ltd. specializes in regenerative medicine and cell therapy solutions. In December 2024, Hisamitsu Pharmaceutical Co.

, Inc. acquired ReEir Co. , Ltd. As of 2024, the company is led by its representative director, Rika Tanaka.

ReEir specializes in the development and commercialization of regenerative medicine and cell therapy solutions that can be implemented through simple blood collection processes. The firm’s primary aim is to restore connections between patients and society, particularly for those affected by serious illnesses that have severed these ties. By focusing on therapies designed to regenerate and repair damaged tissues, the company addresses critical healthcare needs arising from chronic and severe diseases. ReEir’s products are primarily targeted towards healthcare providers, hospitals, and clinics in Japan and potentially in select international markets, as they seek to enhance patient care and improve quality of life through advanced medical solutions.

ReEir operates on a revenue model through the sale of its cell therapy products, tailored to meet the needs of specific patient demographics suffering from various medical conditions. The December 2024 transaction supports ReEir's growth, enhances Kusuhara’s capabilities, and drives innovation in regenerative medicine and therapies.